Form 8-K BIOGEN INC. For: Feb 03
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P 500, Dow rise on Mideast deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil nears two-month lows on reports of imminent US-Iran peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Biogen (BIIB) Misses Q4 EPS by 29c, Guides FY Below Consensus
February 3, 2021 7:08 AM EST(Updated - February 3, 2021 7:09 AM EST)
Biogen (NASDAQ: BIIB) reported Q4 EPS of $4.58, $0.29 worse than the analyst estimate of $4.87. Revenue for the quarter came in at $2.85 million versus the consensus estimate of $2.8 million.
GUIDANCE:
Biogen sees FY2021 EPS of $17.00-$18.50, versus the consensus of $24.67. Biogen sees FY2021 revenue of $10.45-10.75 billion, versus the consensus of $11.22 billion.
Biogen expects full year 2021 revenue to be between $10.45 billion and $10.75 billion, Non-GAAP diluted EPS to be between $17.00 and $18.50, and capital expenditures to be between $375 million and $425 million.This financial... More
